Farnesoid x receptor agonists for cancer treatment and prevention
作者： Claus Kremoser , Ulrich Deuschle
DOI:
关键词:
摘要: Provided is a Farnesoid X Receptor (FXR) agonist for use in the treatment or prevention of certain cancers, metastases, precancerogenic lesions angiogenesis context cancer patient, wherein administered therapeutically effective amount to patient. Also provided an FXR inducing NDRG2 gene expression tissues reducing rate proliferation, migration, metastasis tumors.
wipo.int
google.co.in 参考文章(72)
Kenneth M. Kosak, Cyclodextrin polymers for carrying and releasing drugs ,(1998)
John D. Kalvelage, Child resistant package assembly for dispensing pharmaceutical medications ,(1993)
Howard C. Ansel, Introduction to pharmaceutical dosage forms ,(1969)
Douglas V. Carter, Method of packaging and sterilizing a pharmaceutical product ,(1987)
Roland Wyatt, Stephen C. Peterson, Tomasz J. Petelenz, Stephen C. Jacobsen, Multipathway electronically-controlled drug delivery system ,(1998)
Misuk Legocki, Thomas O. Baldwin, Roman P. Legocki, Aladar A. Szalay, Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms ,(1987)
Douglas V. Carter, Packaged pharmaceutical product ,(1990)
Robert S. Langer, Hongming Chen, Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery ,(1997)
Alfonso R. Gennaro, Joseph P. Remington, Remington's pharmaceutical sciences Published in <b>1975</b> in Easton Pa) by Mack. ,(1985)
Jean-Marc Plancher, Hans Richter, Sven Taylor, Konrad Bleicher, Uwe Grether, Gregory Martin Benson, Bernd Kuhn, Song Feng, Rainer E. Martin, Markus Rudolph, 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives ,(2009)